Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00459
|
|||||
| Drug Name |
Fluoxetine
|
|||||
| Synonyms |
(+-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-p-tolyl)oxy)propylamine; (+-)-N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine;(+/-)-Fluoxetine; (+/-)-N-Methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine; (+/-)-N-Methyl-3-p-(p-trifluoromethylphenoxy)-3-phenylpropylamine; (+/-)-N-Methyl-3-phenyl-3-[(alpha,alpha,alpha-trifluoro-p-tolyl)oxy]propylamine; (+/-)-N-Methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propylamine]; (+/-)-N-Methyl-gamma-[4-(trifluoromethyl)phenoxy]benzenepropanamine; 3-(p-Trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine; Animex-On; Dl-3-(p-Trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine; Eufor; Floxetine; Fluoxetin; Fluoxetina; Fluoxetina [INN-Spanish]; Fluoxetina [Spanish]; Fluoxetine (Prozac); Fluoxetine (TN); Fluoxetine (USAN/INN); Fluoxetine Hcl; Fluoxetine [USAN:INN:BAN]; Fluoxetinum; Fluoxetinum [INN-Latin]; Fluval; Fontex; Lilly-110140; Methyl({3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl})amine; Methyl-[3-phenyl-3-(4-trifluoromethyl-phenoxy)-propyl]-amine; N-Methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine; N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine; N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine; N-methyl-3-phenyl-3-{[4-(trifluoromethyl)phenyl]oxy}propan-1-amine; Portal; Prozac (TN); Prozac Weekly; Pulvules; Reconcile; Reneuron
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Depression [ICD11:6A8Z] | Approved | [1] | |||
| Therapeutic Class |
Antidepressants
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C17H18F3NO
|
|||||
| Canonical SMILES |
CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F
|
|||||
| InChI |
InChI=1S/C17H18F3NO/c1-21-12-11-16(13-5-3-2-4-6-13)22-15-9-7-14(8-10-15)17(18,19)20/h2-10,16,21H,11-12H2,1H3
|
|||||
| InChIKey |
RTHCYVBBDHJXIQ-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 54910-89-3
|
|||||
| Pharmaceutical Properties | Molecular Weight | 309.33 | Topological Polar Surface Area | 21.3 | ||
| Heavy Atom Count | 22 | Rotatable Bond Count | 6 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 5 | |||
| XLogP |
4
|
|||||
| PubChem CID | ||||||
| PubChem SID |
11341994
,11362177
,11364573
,11367135
,11369697
,11372694
,11374305
,11377859
,11466539
,11467659
,11485551
,11486118
,11487579
,11489474
,11491463
,11492428
,11495493
,143844
,14874184
,26751973
,29222521
,3249391
,3719648
,46507902
,47365860
,47515964
,47515965
,47589652
,47662955
,47960412
,48111113
,48259912
,48259913
,48416026
,49698967
,49833486
,49880992
,50104648
,50319599
,5367839
,53787367
,56312230
,56312679
,56312978
,56313632
,57321770
,7847392
,7979254
,8152157
,841244
|
|||||
| ChEBI ID |
ChEBI:5118
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | Fluoxetine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Fluoxetine and reversal of multidrug resistance. Cancer Lett. 2006 Jun 18;237(2):180-7. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.